Evoxac capsules 30 mg for dry mouth (Sjogren's syndrome, cevimeline, Saligren)

General information on Japanese Evoxac capsules 30 mg for dry mouth (Sjogren's syndrome, cevimeline, Saligren)

Package details: 100 capsules

Manufacturer: Daiichi Sankyo Co., Ltd., Japan

Active ingredient: cevimeline hydrochloride hydrate (chemical formula (C10H17NOS)2. 2HCl. H2O)

Medical effect: Evoxac capsules are effective for the treatment of oral dryness in the patients with Sjogren's syndrome.

Contraindications and precautions: do not use for the following categories of patients:

• pregnant and breastfeeding women,
• patients with ischemic heart disease (myocardial infarction, angina pectoris etc.),
• patients with bronchial asthma or chronic obstructive pulmonary disease,
• patients with gastrointestinal obstruction or urinary bladder neck obstruction,
• patients with epilepsy,
• patients with Parkinsonian syndrome or Parkinson's disease,
• patients with iritis.

If an allergic reaction occurs, stop taking the medicine and consult with your doctor. If you’re taking any other medication, please consult with your doctor before use.

As this medicine may cause miosis, patients should take care when driving a car during the evening, or operating dangerous machinery in a dark place.

Dosage and administration of Evoxac capsules 30 mg from Japan for dry mouth (Sjogren's syndrome, cevimeline, Saligren)

For adults, take 1 capsule (30 mg of the active ingredient) 3 times a day after meals.

How effective are Evoxac capsules 30 mg from Japan for dry mouth (Sjogren's syndrome, cevimeline, Saligren)?

Evoxac capsules’ active ingredient is cevimeline hydrochloride hydrate. It is a parasympathomimetic and muscarinic agonist that activates M1 and M3 receptors of the parasympathetic nervous system. By this, Evoxac capsules stimulate secretion of the salivary glands and promotes salivation.

Who should take Evoxac capsules 30 mg from Japan?

Studies showed that 30 mg capsules of cevimeline hydrochloride within 52 weeks have increased salivary flow and improved subjective and objective symptoms in patients with Sjogren's syndrome (A. Shiozawa. Cevimeline hydrochloride hydrate: A review of its pharmacological profiles and clinical potential in xerostomia (in Japanese language). Folia Pharmacologica Japonica, 2002, November, 120(4): 253-8). Also, Evoxac capsules are found to be effective for the treatment of dry mouth in patients with psychosomatic oral disease.